Is there a Mounjaro pill, or does it only come as an injection?

The misconception: if semaglutide has a pill, surely Mounjaro does too?

This is probably the most common assumption our prescribers come across on this topic, and it's easy to see where it comes from. Wegovy tablets launched in the UK in June 2026, making semaglutide the first oral GLP-1 medicine licensed here for weight loss. Once that became news, the natural next thought was: has Mounjaro done the same?

It hasn't, and the reason is partly chemistry. Semaglutide is a single-receptor agonist, and Novo Nordisk spent years developing the SNAC absorption-enhancer technology that allows it to survive the digestive system well enough to reach the bloodstream in useful quantities. Tirzepatide is a dual-agonist molecule, targeting both the GIP and GLP-1 receptors simultaneously. Formulating a larger, more complex peptide for reliable oral absorption is a harder engineering problem, and Eli Lilly hasn't published a licensed oral tirzepatide product for the UK. That's the current reality, not a rumour, not a gap in coverage.

It's worth letting that misconception go gently, because it does matter for your decision-making. If you're set on an oral GLP-1 medicine today, the only licensed option in the UK is the Wegovy tablet. If tirzepatide's dual mechanism interests you, the injection route is, for now, the only route. Neither is better by definition, they're different medicines with different trial profiles.

What Mounjaro actually is and how it's taken

Mounjaro is the brand name for tirzepatide, made by Eli Lilly. It works by activating both the GIP and the GLP-1 receptors, gut hormones that influence appetite, feelings of fullness and how quickly the stomach empties. The tirzepatide molecule itself is a synthetic dual-agonist peptide, which is why it can't simply be swallowed like a paracetamol; stomach acid would break it down before it could be absorbed.

The KwikPen delivers the medicine directly under the skin (typically the abdomen, thigh or upper arm) once a week on the same day each week. Treatment starts at 2.5mg, a dose designed to give the body time to adjust rather than to produce immediate weight loss, and the prescriber reviews and adjusts the dose over time. UK-licensed strengths run from 2.5mg through to 15mg in six steps. Storage requires a fridge (2–8°C); the exact room-temperature window is specified in the Patient Information Leaflet and varies, so always follow those instructions rather than a general rule. The NHS medicines page for tirzepatide gives a clear patient-level overview of how the medicine is given and what to expect.

For people who are genuinely concerned about injections, that concern is worth raising at the consultation stage, our prescribers can discuss technique, auto-needle covers and what the injection actually feels like in practice. Most people find it far less significant than they expected.

The oral option that does exist: semaglutide tablets

If an injection-free approach matters to you, there is now a licensed UK alternative worth knowing about. The MHRA approved Wegovy tablets on 11 June 2026, the UK was the first country in Europe to license an oral GLP-1 medicine for weight management. It contains semaglutide (the same active ingredient as Wegovy injections) co-formulated with an absorption enhancer called SNAC.

In the OASIS 4 phase-3 trial, participants lost an average of around 13.6% of body weight over 64 weeks alongside lifestyle changes, rising to roughly 17% among those who adhered fully to the treatment schedule. Those who stayed on the injection form of semaglutide at 2.4mg saw approximately 15% average weight loss over 68 weeks in the STEP 1 trial, published in the New England Journal of Medicine. The tablet does require a specific morning routine: first thing on an empty stomach, with a small amount of plain water, waiting at least 30 minutes before any food, coffee or other oral medicines. No refrigeration needed, which makes it travel-friendly.

The tablet is a different medicine from Mounjaro, not a tablet version of it. Whether it's the right choice for any individual is a clinical decision. You can explore the broader landscape of weight-loss treatments available through nume if you want a starting point before a consultation.

Is an oral tirzepatide on the horizon?

Eli Lilly is researching oral formulations of tirzepatide, and early-phase clinical data has been published. However, no oral tirzepatide product has received UK marketing authorisation, and the timeline for any such approval is not confirmed. What's available now is the injection. If this landscape changes, MHRA approval would need to come before any licensed product could be dispensed by a UK pharmacy. For a more detailed look at whether an oral tirzepatide is in development, that page covers the pipeline in more depth.

The practical takeaway for now: if you want tirzepatide, it comes as an injection. If you want an oral GLP-1 medicine licensed for weight management, semaglutide tablets are the only current option. Both are prescription-only medicines, and both require a clinical assessment before a prescriber can decide whether either is appropriate. Understanding how Mounjaro works in full (not just the delivery mechanism but the eligibility criteria, the evidence and the commitment involved) makes that conversation much more productive. If cost is also a factor in your thinking, our guide to Mounjaro pricing in the UK puts the numbers in honest context. When you're ready, our prescribers are available to assess your situation seven days a week.